Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Net Income (2016 - 2025)

Anika Therapeutics has reported Net Income over the past 16 years, most recently at -$1.5 million for Q4 2025.

Quarterly Net Income rose 92.21% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14000.0 through Mar 2026, up 100.03% year-over-year, with the annual reading at -$901000.0 for FY2025, 98.11% up from the prior year.
Net Income was -$1.5 million for Q4 2025 at Anika Therapeutics, down from $846000.0 in the prior quarter.
Over five years, Net Income peaked at $17.1 million in Q4 2023 and troughed at -$28.1 million in Q3 2024.
The 5-year median for Net Income is -$2.0 million (2024), against an average of -$2.8 million.
Year-over-year, Net Income plummeted 845.88% in 2022 and then surged 188.56% in 2024.
A 5-year view of Net Income shows it stood at -$10.7 million in 2021, then soared by 156.56% to $6.1 million in 2022, then skyrocketed by 181.25% to $17.1 million in 2023, then tumbled by 213.33% to -$19.4 million in 2024, then soared by 92.21% to -$1.5 million in 2025.
Per Business Quant, the three most recent readings for ANIK's Net Income are -$1.5 million (Q4 2025), $846000.0 (Q3 2025), and $677000.0 (Q2 2025).